Information Provided By:
Fly News Breaks for May 3, 2019
ACHN
May 3, 2019 | 08:56 EDT
Barclays analyst Geoffrey Meacham downgraded Achillion Pharmaceuticals to Underweight from Equal Weight and cut his price target for the shares to $2.50 from $5. The analyst sees a lack of near- to mid-term catalysts that are capable of changing the story on the stock. He notes the downgrade has less to do with the underlying fundamentals of Achillion's Factor D program.
News For ACHN From the Last 2 Days
There are no results for your query ACHN